On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying AbbVie Inc. ABBV, saying it's “just a gem” and a “winner.”  He added, “I can't believe the stock dropped so much.”

On Jan. 31, AbbVie reported fourth-quarter adjusted earnings per share of $2.16, beating the street view of $2.11. Quarterly sales of $15.102 billion, outpacing the analyst consensus estimate of $14.827 billion. Several analysts also raised their price targets on the stock following the earnings announcement.

Cramer Shares His Views On These Tech Stocks

MongoDB MDB is a trade and not an investment, Cramer said. “You'd be catching it at the right time. I think the analysts are all starting to upgrade the, the enterprise software again. I think it's worth a stab, I really do.”

In the recent news, MongoDB has partnered with Lombard Odier to modernize core banking technology with generative AI.

The Mad Money host recommended pulling the trigger on Cerence Inc. CRNC.

On the earnings front, Cerence is scheduled to announce its first quarter financial results on Thursday, Feb. 6.

Other Stocks In Focus

Cramer recommended buying Bitcoin BTC/USD instead of going with Coinbase Global, Inc. COIN.

Supporting his view, Keefe, Bruyette & Woods analyst Kyle Voigt, on Jan. 13, maintained Coinbase with a Market Perform and lowered the price target from $275 to $255.

Stryker SYK is the better one, Cramer said when asked about Tempus AI, Inc. TEM. “If you want AI, then you go with Medtronic MDT.”

Supporting that view, Loop Capital analyst Mark Schappel, on Jan. 14, maintained Tempus AI with a Buy and lowered the price target from $57 to $52.

Price Action:

• MongoDB shares gained 2.7% to settle at $275.97 on Tuesday.
• Tempus shares gained 0.5% to close at $61.85 during the session.
• Coinbase shares fell 1.4% to settle at $280.39.
• AbbVie shares fell 0.1% to close at $189.95 on Tuesday.
• Cerence shares gained 6.2% to settle at $12.07.

Read Next:

• Jim Cramer Says No To BigBear.ai, Recommends Buying This Tech Stock